Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 82.

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Hosts David and Gina explore how scientists over the centuries unlocked the ability to edit our genes ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CRISPR Therapeutics AG before investing. In this article, we go over a few key ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA — often ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

Last August, KJ Muldoon was born with a potentially fatal genetic disorder. Just six months later, he received a Crispr treatment designed just for him. Muldoon has a rare disorder known as CPS1 ...